Rosiglitazone Prevents High Glucose-Induced Vascular Endothelial Growth Factor and Collagen IV Expression in Cultured Mesangial Cells

Figure 4

Rosiglitazone prevented high glucose-induced VEGF expression . Mesangial cells were placed in 5.6 mM (NG) or 25 mM (HG) D-glucose for the indicated times or pretreated with PPAR𝛾 agonists (10 𝜇M Ciglitazone, or 10 𝜇M Troglitazone, or 10 𝜇M RGS) for 1 hour. (a) VEGF mRNA levels were detected by real-time PCR (𝑛=4, ^∗𝑃<.05 versus NG, ^∗∗𝑃<.01 versus HG). (b) Pretreatment with three different PPAR𝛾 agonists similarly blocked HG-induced VEGF expression at 48 hours as detected by immunobloting (𝑛=4, ^∗𝑃<.01 versus NG, ^∗∗𝑃<.01 versus HG). (c) Rosiglitazone alone prevented HG-induced VEGF expression at both 24 hours and 48 hours as detected by immunoblotting in total cell lysates using 𝛽-actin as the loading control. The graphs represent VEGF protein levels relative to NG (𝑛=5, ^∗𝑃<.01 versus NG, ^∗∗𝑃<.01 versus HG). (d) GW9662 reverses the effect of RSG, (𝑛=5, ^∗𝑃<.01 versus NG without RSG or GW9662 , ^∗∗𝑃<.001 versus NG without RSG or GW9662).

(a)

(b)

(c)

(d)